🟢 Context Therapeutics is trading 6.5% up in pre-market, with no clear company-specific catalyst identified

Context Therapeutics is trading 6.5% higher at $0.32 in pre-market on October 1, 2026, with no clear company-specific catalyst identified.

• Shares closed at $0.30 on September 30 after declining over the preceding six sessions; the pre-market gain reverses that trend.
• The latest listed company press release, dated September 9, announced the first patient dosed in the Phase 1 CT-202 trial, but does not establish a reason for the move.